Hospitals & health systems
Adverse drug reactions are linked to 3–6% of U.S. hospital admissions, and drugs with known PGx annotations account for about 30% of ADRs at admission.5 A turnkey send-out program puts that information on file before future prescribing decisions, with no lab build, no validation cost and no new staff.
A patient's genetic profile doesn't change. Their medication list does.
Hospitalized patients are often on many medications and start new ones fast. PGx results give prescribers and pharmacists drug-gene insight at the point of care, and stay useful for the rest of the patient's life.
- Flag drug-gene interactions for future prescribing. Swab at admission, pre-op or discharge so results are on file.
- Designed to help reduce adverse drug events and trial-and-error prescribing. Almost half of spontaneously reported ADRs may have identifiable causes, most likely explained by genetic variability.5
- Evidence on readmissions and ED returns. In a pilot randomized trial of 110 home health patients age 50+, PGx-guided care was associated with 52% fewer rehospitalizations and 42% fewer ED visits at 60 days.4
A send-out test with nothing to build
No validation costs
A send-out test performed in AchieveDx's own CLIA high-complexity lab. No equipment, validation or added lab cost.
No new staff
The program team handles enrollment, benefits verification, clinical review and results delivery.
Coverage verified
Eligibility is checked with each patient's plan before the test runs.
Who benefits most from PGx testing
Flag candidates with simple criteria across the service lines where drug-gene interactions matter most.
Polypharmacy
Patients on five or more medications
Cardiology
Clopidogrel, warfarin and statin therapy
Pain management
Opioids such as codeine and tramadol, plus NSAIDs
Behavioral health
Antidepressants and antipsychotics
Neurology
Antiseizure medications such as phenytoin
Oncology
Hormone therapy such as tamoxifen
These are clinical flags, not coverage criteria. Coverage requires a specific medication decision.
Everything your team needs, ready on day one
You get the program, the tools, the process and hands-on onboarding.
The program
Send-out PGx testing through AchieveDx's CLIA high-complexity lab.
The tools
Patient identification criteria, requisitions and patient education materials.
The process
An eight-step workflow managed end to end.
Onboarding
We walk your team through ordering, collection and results so the program runs smoothly from day one.
From patient identification to results for the care team
- Step 1
Patient identification
Eligible patients identified by service line and medication profile.
- Step 2
Physician's order
The treating physician orders the PGx test.
- Step 3
Patient consent
Patient education and informed consent collection.
- Step 4
Sample collection
A simple cheek swab collected on-site.
- Step 5
Ship to lab
Samples ship to our CLIA high-complexity lab.
- Step 6
Results delivered
Completed results are delivered securely to the care team.
- Step 7
Pharmacist interprets
A pharmacist flags clinically relevant drug-gene interactions.
- Step 8
Physician reviews
The physician reviews the interpretation and adjusts therapy as needed.
The business case for preemptive PGx
Published studies have reported lower hospitalization rates and a trend toward lower total cost of care with PGx-guided prescribing.
trend toward lower annual cost of care per tested patient in one community health system's Medicare Advantage population, versus matched untested controls (observational, 548 patients).6
El Rouby N, et al. Clin Transl Sci, 2025fewer all-cause hospital admissions with PGx-guided care (11.5% vs 20.1%), pooled across five U.S. studies.7
David V, et al. Frontiers in Genetics, 2021A 2024 scientific statement concluded the evidence to date supports CYP2C19 testing before oral P2Y12 inhibitors in ACS and PCI.9
Pereira NL, et al. Circulation, 2024Figures come from published studies of PGx-guided care in other programs and populations. They are not results of AchieveDx's test. See references.
How a hospital program launches
- Step 1
Scope
Pick the units, patient cohorts and test lines to start with.
- Step 2
Set up
Confirm requisitions, courier schedule and how results are delivered.
- Step 3
Pilot
A time-boxed pilot on an agreed patient group.
- Step 4
Review & expand
Review turnaround, utilization and outcomes together, then scale.
Oncology NGS for your cancer program
Hereditary, somatic and liquid biopsy panels with Celemics, delivered as interpreted reports.